Sandoz receives European Commission approval for Wyost and Jubbonti, biosimilars of denosumab
The European Commission (EC) has granted marketing authorization for Sandoz’s Wyost® (denosumab) and Jubbonti® (denosumab), the first and only biosimilar versions of reference medicines Xgeva® and Prolia® in Europe. Wyost® is approved for the treatment of …